Nasopharyngeal Cancinoma (NPC) Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Nasopharyngeal Cancinoma (NPC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University243 enrolled4 locationsNCT07362979
Recruiting
Phase 3

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University550 enrolled1 locationNCT07201337
Recruiting
Phase 2

LDRT and Chemoimmunotherapy in NPC With Liver Metastasis

Nasopharyngeal Cancinoma (NPC)
Hunan Cancer Hospital26 enrolled7 locationsNCT06788002
Recruiting
Phase 2

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

Nasopharyngeal Cancinoma (NPC)
Fudan University76 enrolled1 locationNCT07067268
Recruiting
Phase 3

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Nasopharyngeal CancerNasopharyngeal Cancinoma (NPC)
Sun Yat-Sen University Cancer Center580 enrolled19 locationsNCT06749899
Recruiting
Phase 1Phase 2

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharynx Carcinoma
Sun Yat-Sen University Cancer Center148 enrolled1 locationNCT06802835
Recruiting

A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)

Lymph Node MetastasisNasopharyngeal Cancinoma (NPC)
Sun Yat-sen University500 enrolled1 locationNCT06829147